<DOC>
	<DOCNO>NCT01996306</DOCNO>
	<brief_summary>The primary purpose study determine non-inferiority overall survival XELIRI without Bevacizumab compare FOLFIRI without Bevacizumab Second-line therapy Patient Metastatic Colorectal Cancer .</brief_summary>
	<brief_title>A Phase III Study 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab mCRC</brief_title>
	<detailed_description>Primary endpoint : Overall survival ( OS ) , Secondary endpoint : Progression-free survival ( PFS ) , Time treatment failure ( TTF ) , Overall response rate ( ORR ) , Disease Control Rate ( DCR ) , Relative dose intensity , Safety , Correlation UGT1A1 genotype Safety .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Histologicallyconfirmed inoperable colorectal adenocarcinoma exclude vermiform appendix cancer anal canal cancer . 2 . Age ≥20 year time inform consent 3 . ECOG performance status ( PS ) 02 4 . Written inform consent prior studyspecific screening procedure 5 . Life expectancy least 90 day 6 . Withdrawal firstline chemotherapy ( regardless containing moleculartargeted drug ) metastatic colorectal cancer due intolerable toxicity progressive disease , relapse within 180 day last dose adjuvant chemotherapy . 7 . Adequate organ function accord follow laboratory value obtain within 14 day enrolment ( exclude patient receive blood transfusion hematopoietic growth factor within 14 day laboratory test ) Neutrophil count : ≥1500/mm3 Platelet count : ≥10.0 x 104/mm3 Hemoglobin : ≥9.0 g/dL Total bilirubin : ≤1.5 mg/dL AST , ALT : ≤100 IU/L ( ≤200 IU/I liver metastasis present ) Serum creatinine : ≤1.5 mg/dL 1 . History malignancy diseasefree interval &lt; 5 year ( curatively treat cutaneous basal cell carcinoma , curatively treat carcinoma situ cervix , gastroenterological cancer confirm cured endoscopic mucosal resection ) 2 . With massive pleural effusion ascites require intervention 3 . Radiological evidence brain tumor brain metastases 4 . Active infection include hepatitis 5 . Any following complication : ) Gastrointestinal bleed gastrointestinal obstruction ( include paralytic ileus ) ii ) Symptomatic heart disease ( include unstable angina , myocardial infarction , heart failure ) iii ) Interstitial pneumonia pulmonary fibrosis iv ) Uncontrolled diabetes mellitus v ) Uncontrolled diarrhea ( interferes daily activity despite adequate therapy ) 6 . Any following medical history : Myocardial infarction : History one episode within one year enrollment two lifetime episode ) Serious hypersensitivity study drug ii ) History adverse reaction fluoropyrimidines suggest dihydropyrimidine dehydrogenase ( DPD ) deficiency 7 . Previous treatment irinotecan hydrochloride 8 . Current treatment atazanavir sulfate 9 . Previous treatment tegafur , gimeracil , oteracil potassium within seven day enrollment 10 . Pregnant lactating female , male female unwilling use contraception 11 . Requires continuous treatment systemic steroid 12 . Psychiatric disability would preclude study compliance 13 . Otherwise determined investigator unsuitable participation study 14 . Concurrent gastrointestinal perforation history gastrointestinal perforation 1 year enrollment 15 . History pulmonary hemorrhage/hemoptysis ≥ Grade 2 ( define bright red blood least 2.5mL ) within 1 month prior enrollment . 16 . History laparotomy , thoracotomy , intestinal resection within 28 day enrollment 17 . Unhealed wound ( except suture wound implantation central venous port ) , gastrointestinal ulcer , traumatic fracture 18 . Current recent ( within 1 year ) thromboembolism cerebrovascular disease 19 . Currently receive require anticoagulation therapy ( &gt; 325 mg/day aspirin ) 20 . Bleeding diathesis , coagulopathy , coagulation factor abnormality ( INR ≥1.5 within 14 day enrollment ) 21 . Uncontrolled hypertension 22 . Urine dipstick proteinuria &gt; +2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>AXEPT</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>CPT-11</keyword>
	<keyword>XELIRI</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>FOLFIRI</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>2nd-line metastatic colorectal cancer</keyword>
</DOC>